Stacie B Dusetzina

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. pmc Changes in antipsychotic use among patients with severe mental illness after a Food and Drug Administration advisory
    Stacie B Dusetzina
    Department of Health Care Policy, Harvard Medical School, Boston, MA, USA
    Pharmacoepidemiol Drug Saf 21:1251-60. 2012
  2. ncbi Treatment use and costs among privately insured youths with diagnoses of bipolar disorder
    Stacie B Dusetzina
    Department of Health Care Policy, Harvard Medical School, 180 Longwood Ave, Boston, MA 02115, USA
    Psychiatr Serv 63:1019-25. 2012
  3. doi Prevalence of bipolar disorder diagnoses and psychotropic drug therapy among privately insured children and adolescents
    Stacie B Dusetzina
    Department of Health Care Policy, Harvard Medical School, Boston, MA 02115, USA
    Pharmacotherapy 32:1085-94. 2012
  4. pmc Racial-ethnic differences in incident olanzapine use after an FDA advisory for patients with schizophrenia
    Stacie B Dusetzina
    Department of Health Care Policy, Harvard Medical School, 180 Longwood Ave, Boston, MA 02115, USA
    Psychiatr Serv 64:83-7. 2013
  5. doi Receipt of guideline-concordant pharmacotherapy among children with new diagnoses of bipolar disorder
    Stacie B Dusetzina
    Department of Health Care Policy, Harvard Medical School, Boston, MA 02115, USA
    Psychiatr Serv 62:1443-9. 2011
  6. doi Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia
    Stacie B Dusetzina
    Stacie B Dusetzina, School of Medicine and Lineberger Comprehensive Cancer Center and Cecil G Sheps Center for Health Services Research Stacie B Dusetzina and Aaron N Winn, Gillings School of Global Public Health University of North Carolina at Chapel Hill, Chapel Hill, NC Gregory A Abel, Dana Farber Cancer Institute Haiden A Huskamp and Nancy L Keating, Harvard Medical School and Nancy L Keating, Brigham and Women s Hospital, Boston, MA
    J Clin Oncol 32:306-11. 2014
  7. pmc Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review
    Stacie B Dusetzina
    Department of Health Care Policy, Harvard Medical School, Boston, MA, USA
    Med Care 50:466-78. 2012
  8. pmc Medicare Part D plan generosity and medication use among dual-eligible nursing home residents
    Haiden A Huskamp
    Department of Health Care Policy, Harvard Medical School, Boston, MA The Dartmouth Institute and Geisel Medical School at Dartmouth, Lebanon, NH Division of General Medicine and Clinical Epidemiology, School of Medicine Department of Health Policy and Management, Gillings School of Global Public Health Cecil G Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, Chapel Hill, NC Institute for Aging Research, Hebrew SeniorLife, Deaconess Medical Center Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA Omnicare Inc, Livonia, MI Department of Health Policy and Management, Harvard School of Public Health, Boston Harvard Kennedy School, Cambridge, MA
    Med Care 51:894-900. 2013

Detail Information

Publications8

  1. pmc Changes in antipsychotic use among patients with severe mental illness after a Food and Drug Administration advisory
    Stacie B Dusetzina
    Department of Health Care Policy, Harvard Medical School, Boston, MA, USA
    Pharmacoepidemiol Drug Saf 21:1251-60. 2012
    ..We examine subsequent changes in incident and prevalent SGA use among individuals with severe mental illness...
  2. ncbi Treatment use and costs among privately insured youths with diagnoses of bipolar disorder
    Stacie B Dusetzina
    Department of Health Care Policy, Harvard Medical School, 180 Longwood Ave, Boston, MA 02115, USA
    Psychiatr Serv 63:1019-25. 2012
    ..The objectives of the study were to identify one-year health services utilization and treatment costs among youths newly diagnosed as having bipolar disorder...
  3. doi Prevalence of bipolar disorder diagnoses and psychotropic drug therapy among privately insured children and adolescents
    Stacie B Dusetzina
    Department of Health Care Policy, Harvard Medical School, Boston, MA 02115, USA
    Pharmacotherapy 32:1085-94. 2012
    ..To estimate the treated prevalence of bipolar disorder in a privately insured population, describe the characteristics of children and adolescents receiving these diagnoses, and describe patterns of their psychotropic drug therapy...
  4. pmc Racial-ethnic differences in incident olanzapine use after an FDA advisory for patients with schizophrenia
    Stacie B Dusetzina
    Department of Health Care Policy, Harvard Medical School, 180 Longwood Ave, Boston, MA 02115, USA
    Psychiatr Serv 64:83-7. 2013
    ..S. Food and Drug Administration (FDA) communication and consensus statement warning of the drug's increased metabolic risks, but whether declines differed by racial-ethnic groups is unknown...
  5. doi Receipt of guideline-concordant pharmacotherapy among children with new diagnoses of bipolar disorder
    Stacie B Dusetzina
    Department of Health Care Policy, Harvard Medical School, Boston, MA 02115, USA
    Psychiatr Serv 62:1443-9. 2011
    ..This study examined the extent to which children with bipolar I disorder received recommended treatment of mood-stabilizer or second-generation antipsychotic monotherapy and factors associated with its receipt...
  6. doi Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia
    Stacie B Dusetzina
    Stacie B Dusetzina, School of Medicine and Lineberger Comprehensive Cancer Center and Cecil G Sheps Center for Health Services Research Stacie B Dusetzina and Aaron N Winn, Gillings School of Global Public Health University of North Carolina at Chapel Hill, Chapel Hill, NC Gregory A Abel, Dana Farber Cancer Institute Haiden A Huskamp and Nancy L Keating, Harvard Medical School and Nancy L Keating, Brigham and Women s Hospital, Boston, MA
    J Clin Oncol 32:306-11. 2014
    ..We examined trends in imatinib expenditures from 2002 to 2011 and assessed the association between copayment requirements for imatinib and TKI adherence...
  7. pmc Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review
    Stacie B Dusetzina
    Department of Health Care Policy, Harvard Medical School, Boston, MA, USA
    Med Care 50:466-78. 2012
    ..To review literature on the impact of The Food and Drug Administration (FDA) drug risk communications on medication utilization, health care services use, and health outcomes...
  8. pmc Medicare Part D plan generosity and medication use among dual-eligible nursing home residents
    Haiden A Huskamp
    Department of Health Care Policy, Harvard Medical School, Boston, MA The Dartmouth Institute and Geisel Medical School at Dartmouth, Lebanon, NH Division of General Medicine and Clinical Epidemiology, School of Medicine Department of Health Policy and Management, Gillings School of Global Public Health Cecil G Sheps Center for Health Services Research, University of North Carolina at Chapel Hill, Chapel Hill, NC Institute for Aging Research, Hebrew SeniorLife, Deaconess Medical Center Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA Omnicare Inc, Livonia, MI Department of Health Policy and Management, Harvard School of Public Health, Boston Harvard Kennedy School, Cambridge, MA
    Med Care 51:894-900. 2013
    ..Therefore, residents' assigned plans may be relatively more or less generous for their particular drugs. The impact of generosity on residents' medication use and health outcomes is unknown...